Research Article| Volume 107, P138-143, January 2023

Elevated ApoB/ApoA-Ι ratio is associated with poor outcome in acute ischemic stroke

Published:November 16, 2022DOI:


      • Higher ApoB, lower ApoA-Ι, higher ApoB/ApoA-Ι ratio were independently associated with poor outcome in acute ischemic stroke.
      • ApoB and ApoA-Ι were not related to the transformation of intracranial hemorrhage in acute ischemic stroke.
      • ApoB/ApoA-Ι ratio was more likely associated with poor outcomes of AIS in the patients of small artery occlusion.



      Apolipoproteins are known atherogenic factors that play important roles in many mechanisms related to acute ischemic stroke (AIS). However, it is unclear whether the ApoB/ApoA-Ι ratio is related to the prognosis of patients with AIS.


      We conducted a prospective cohort study in the Department of Neurology, Yangpu Hospital, School of Medicine, Tongji University and investigated the association between ApoB/ApoA-Ι ratio and poor outcomes at 3 months of AIS.


      1,247 patients that met the eligibility criteria were enrolled in our study. We found that ApoA-Ι (Adjusted odds ratios (adjOR) 0.529, 95 %CI 0.327–0.855), ApoB (adjOR 3.015, 95 %CI 1.746–5.207), and ApoB/ApoA-Ι ratio (adjOR 3.986, 95 %CI 2.220–7.155) were independently associated with poor outcomes in acute ischemic stroke. During subgroup analysis, the ApoB/ApoA-Ι ratio was more likely associated with poor AIS outcomes in males and patients younger than 80 with SAO(Small Artery Occlusion) and no history of diabetes or statin use. Restricted cubic spline analyses explored the correlation between poor outcomes and ApoB/ApoA-Ι ratio.


      Higher ApoB, lower ApoA-Ι, and higher ApoB/ApoA-Ι ratios were independently associated with poor outcomes in AIS. However, ApoB and ApoA-Ι were not related to hemorrhagic transformation in AIS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Feigin V.L.
        • Brainin M.
        World Stroke Organization (WSO).
        Global Stroke Fact Sheet. 2022; 2022: 18-29
      1. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology. 2021; 20: 795-820.

        • Bolanos-Garcia V.M.
        • Miguel R.N.
        On the structure and function of apolipoproteins: more than a family of lipid-binding proteins.
        Prog Biophys Mol Biol. 2003; 83: 47-68
      2. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140-205.

        • Olofsson S.O.
        • Borèn J.
        Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
        J Intern Med. 2005; 258: 395-410
        • Morita S.Y.
        Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis.
        Biol Pharm Bull. 2016; 39: 1-24
        • van der Vorst E.P.C.
        High-Density Lipoproteins and Apolipoprotein A1.
        Sub-cellular biochemistry. 2020; 94: 399-420
        • Walldius G.
        • Jungner I.
        The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy–a review of the evidence.
        J Intern Med. 2006; 259: 493-519
        • Dong H.
        • Chen W.
        • Wang X.
        • et al.
        Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study.
        Metab Brain Dis. 2015; 30: 1319-1330
        • O'Donnell M.J.
        • Chin S.L.
        • Rangarajan S.
        • et al.
        Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.
        Lancet (London, England). 2016; 388: 761-775
        • Adams Jr., H.P.
        • Bendixen B.H.
        • Kappelle L.J.
        • et al.
        Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
        Stroke. 1993; 24: 35-41
        • Hacke W.
        • Kaste M.
        • Fieschi C.
        • et al.
        Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Second European-Australasian Acute Stroke Study Investigators.
        Lancet (London, England). 1998; 352:: 1245-1251
        • Sniderman A.D.
        • Williams K.
        • Contois J.H.
        • et al.
        A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.
        Circulation Cardiovascular quality and outcomes. 2011; 4: 337-345
        • Kaneva A.M.
        • Potolitsyna N.N.
        • Bojko E.R.
        • Odland J.
        The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.
        Dis Markers. 2015; 2015591454
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • et al.
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
        Lancet (London, England). 2004; 364: 937-952
        • Sierra-Johnson J.
        • Fisher R.M.
        • Romero-Corral A.
        • et al.
        Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.
        Eur Heart J. 2009; 30: 710-717
        • Kastelein J.J.
        • van der Steeg W.A.
        • Holme I.
        • et al.
        Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
        Circulation. 2008; 117: 3002-3009
        • Bodde M.C.
        • Hermans M.P.J.
        • Jukema J.W.
        • et al.
        Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up.
        Clinical research in cardiology : official journal of the German Cardiac Society. 2019; 108: 520-538
        • Tian M.
        • Li R.
        • Shan Z.
        • Wang D.W.
        • Jiang J.
        • Cui G.
        Comparison of Apolipoprotein B/A1 ratio, Framingham risk score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention.
        Lipids Health Dis. 2019; 18: 202
        • O'Donnell M.J.
        • Xavier D.
        • Liu L.
        • et al.
        Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.
        Lancet (London, England). 2010; 376: 112-123
        • Bhatia M.
        • Howard S.C.
        • Clark T.G.
        • et al.
        Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack.
        Cerebrovascular diseases (Basel, Switzerland). 2006; 21: 323-328
        • Menet R.
        • Bernard M.
        • ElAli A.
        Hyperlipidemia in Stroke Pathobiology and Therapy: Insights and Perspectives.
        Front Physiol. 2018; 9: 488
      3. Lasek-Bal A, Jedrzejowska-Szypulka H, Student S, et al. The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2019; 70.

      4. Behbodikhah J and Ahmed S. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. 2021; 11.

        • Glavinovic T.
        • Sniderman A.D.
        Apolipoprotein B: the Rosetta Stone of lipidology.
        Curr Opin Endocrinol Diabetes Obes. 2021; 28: 90-96
      5. Mehta A and Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. 2022; 19: 168-79.

        • Lee C.K.
        • Liao C.W.
        Lipids and Lipoproteins in Health and Disease: Focus on Targeting.
        Atherosclerosis. 2021; 9
        • Park J.H.
        • Hong K.S.
        • Lee J.
        • Kim Y.J.
        • Song P.
        Deep subcortical infarct burden in relation to apolipoprotein B/AI ratio in patients with intracranial atherosclerotic stenosis.
        Eur J Neurol. 2013; 20: 671-680
        • Park J.H.
        • Hong K.S.
        • Lee E.J.
        • Lee J.
        • Kim D.E.
        High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis.
        Stroke. 2011; 42: 3040-3046
        • Kalani R.
        • Krishnamoorthy S.
        • Deepa D.
        • et al.
        Apolipoproteins B and A1 in Ischemic Stroke Subtypes.
        J Stroke Cerebrovascular Diseases. 2020; 29104670
        • Ayata C.
        • Shin H.K.
        • Dileköz E.
        • et al.
        Hyperlipidemia disrupts cerebrovascular reflexes and worsens ischemic perfusion defect.
        J Cerebral Blood Flow Metabolism. 2013; 33: 954-962
        • Regenhardt R.W.
        • Das A.S.
        • Ohtomo R.
        • Lo E.H.
        • Ayata C.
        • Gurol M.E.
        Pathophysiology of Lacunar Stroke: History's Mysteries and Modern Interpretations.
        J Stroke Cerebrovascular Diseases. 2019; 28: 2079-2097